| 1 |
Lynch SV, Pedersen O. The human intestinal microbiome in health and disease[J]. N Engl J Med, 2016, 75(24):2369-2379.
|
| 2 |
Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation?[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(10):573-584.
|
| 3 |
Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis[J]. Dis Colon Rectum, 2007, 50(12):2075-2082; discussion 2082-2084.
|
| 4 |
Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic escherichia coli nissle 1917 is as effective as with standard mesalazine[J]. Gut, 2004, 53(11):1617-1623.
|
| 5 |
陈慕媛，李辉标，陈新林，等.枯草杆菌二联活菌联合美沙拉嗪治疗溃疡性结肠炎Meta分析[J].中国医院药学杂志，2018，38(13):1399-1422.
|
| 6 |
廖煜，杨天文.双歧杆菌三联活菌联合美沙拉嗪治疗中国炎症性肠病患者疗效及安全性的Meta分析[J].山西医科大学学报，2018，49(2):140-147.
|
| 7 |
王友多，陈华.美沙拉嗓联合双歧杆菌四联活菌治疗活动期溃疡性结肠炎的临床观察[J].中国药房，2016，27(3):326-327.
|
| 8 |
邢晔陈，庞智，刘志峰，等.干酪乳杆菌联合美沙拉秦治疗溃疡性结肠炎的疗效和安全性观察[J].中华消化杂志，2016，36(10):703-705.
|
| 9 |
Rodino-Janeiro BK, Vicario M, Alonso-Cotoner C, et al. A review of microbiota and irritable bowel syndrome: future in therapies[J]. Adv Ther, 2018, 35(3):289-310.
|
| 10 |
Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome[J]. N Engl J Med, 2017, 376(26):2566-2578.
|
| 11 |
Hungin APS, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms-an updated evidence-based international consensus[J]. Aliment Pharmacol Ther, 2018, 47(8):1054-1070.
|
| 12 |
Farthing M, Salam MA, Lindberg G, et al. Acute diarrhea in adults and children: a global perspective[J]. J Clin Gastroenterol, 2013, 47(1):12-20.
|
| 13 |
中华预防医学会微生态学分会儿科学组.微生态制剂儿科应用专家共识（2010年10月）[J].中国实用儿科杂志，2011，26(1):20-23.
|
| 14 |
王巍，崔立红.利福昔明片联合双歧杆菌三联活菌胶囊治疗中老年急性感染性腹泻84例[J].中国新药杂志，2016，25(9):1036-1039.
|
| 15 |
中华预防医学会微生态学分会.中国消化道微生态调节剂临床应用专家共识（2016版）[J].中华临床感染病杂志，2016，9(3):193-206.
|
| 16 |
张立波，王沙南.美常安治疗因抗生素使用过量导致肠道菌群失调所致腹泻的疗效[J].中国老年学杂志，2014，6(34):1666-1667.
|
| 17 |
Huang L, Zhu Q, Qu X, et al. Microbial treatment in chronic constipation[J]. Sci China Life Sci, 2018, 61(7):744-752.
|
| 18 |
中华医学会老年医学分会.老年人慢性便秘的评估与处理专家共识[J].中华老年医学杂志，2017，36(4):371-381.
|
| 19 |
朱鸿明，张玫，黄新恩，等.双歧杆菌四联活菌片治疗老年慢性功能性便秘临床观察[J].解放军医药杂志，2018，30(4):88-91.
|
| 20 |
Acharya C, Bajaj JS. Altered microbiome in patients with cirrhosis and complications[J]. Clin Gastroenterol Hepatol, 2019, 17(2):307-321.
|
| 21 |
Gui QF, Lu HF, Zhang CX, et al. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model[J]. Genet Mol Res, 2015, 14(2):5642-5651.
|
| 22 |
Wang YH, Yao N, Wei KK, et al. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis[J]. Eur J Clin Nutr, 2016, 70(11):1246-1253.
|
| 23 |
谭国柱，杨福利，刘强.枯草杆菌肠球菌二联活菌胶囊治疗化疗相关性腹泻疗效观察[J].山东医药，2010，26(50):59.
|
| 24 |
杜振华，潘雪.整肠生预防急性放射性肠炎的疗效观察[J].中国微生态学杂志，2017，6(29):715-717.
|
| 25 |
de Clercq NC, Frissen MN, Groen AK, et al. Gut microbiota and the gut-brain axis: new insights in the pathophysiology of metabolic syndrome[J]. Psychosom Med, 2017, 79(8):874-879.
|
| 26 |
Bernini LJ, Simao AN, Alfieri DF, et al. Beneficial effects of bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: a randomized trial. Effects of probiotics on metabolic syndrome[J]. Nutrition, 2016, 32(6):716-719.
|
| 27 |
O'Connor S, Chouinard-Castonguay S, Gagnon C, et al. Prebiotics in the management of components of the metabolic syndrome[J]. Maturitas, 2017 (104):11-18.
|
| 28 |
Manzanares W, Lemieux M, Langlois PL, et al. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis[J]. Crit Care, 2016 (19):262.
|
| 29 |
宋维鹏，刘丽.益生菌联合丙氨酰谷氨酰胺对外科危重患者肠屏障功能的影响[J].海南医学院学报，2015，21(8):1076-1078,1081.
|
| 30 |
魏炜.微生态制剂对危重病患者胃肠功能障碍的治疗作用[J].临床外科杂志，2008，16(6):406-408.
|
| 31 |
张天卿.酪酸梭菌活菌胶囊联合早期肠内营养对危重病患者营养状况及胃肠道并发症的影响[J].药物流行病学杂志，2015，3(24):152-154.
|
| 32 |
杨云梅.老年肠道微生态新进展[J].中华保健医学杂志，2016，18(1):1-6.
|
| 33 |
Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing[J]. Ageing Res Rev, 2010, 9(2):107-116.
|
| 34 |
Lahtinen SJ, Forssten S, Aakko J, et al. Probiotic cheese containing lactobacillus rhamnosus HN001 and lactobacillus acidophilus NCFMR modifies subpopulations of fecal lactobacilli and clostridium difficile in the elderly[J]. Age (Dordr), 2012, 34(1):133-143.
|
| 35 |
Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections[J]. Am J Gastroenterol, 2013, 108(4):478-498; quiz 499.
|
| 36 |
Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66(4):569-580.
|
| 37 |
Konig J, Siebenhaar A, Hogenauer C, et al. Consensus report: faecal microbiota transfer-clinical applications and procedures[J]. Aliment Pharmacol Ther, 2017, 45(2):222-239.
|
| 38 |
中华预防医学会微生态学分会儿科微生态学组.关于儿童粪菌移植的技术规范共识[J].中国微生态杂志，2016，28(4):479-482.
|
| 39 |
Fischer M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of clostridium difficile infection: a multicenter study[J]. Am J Gastroenterol, 2016, 111(7):1024-1031.
|
| 40 |
Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of clostridium difficile infection in immunocompromised patients[J]. Am J Gastroenterol, 2014, 109(7):1065-1071.
|
| 41 |
Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing: a novel delivering way for fecal microbiota transplantation[J]. Endosc Int Open, 2016, 4(6):E610-E613.
|